Tandem Transplant
Customize your policy alerts
Sign up for mhn Policy CP.MP.162 alerts
Get alerted when Policy CP.MP.162 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity criteria and coverage guidance for planned sequential (tandem) high-dose therapy with hematopoietic cell transplant, primarily autologous transplants (and select autologous→allogeneic sequences) for specific malignancies; applies to members/enrollees of the payer.
Updated verbiage I.3.b.ii., I.3.c.i. through iii., and I.A.3.d.; added substance use contraindication I.B.15; removed broader statement limiting indications (criteria IV).
Replaced prior broad contraindications with a new, condensed contraindication list I.B.1 through I.B.6.
Added requirements for tandem autologous followed by reduced-intensity allogeneic transplant from an HLA-identical sibling donor for untreated, newly diagnosed multiple myeloma when contraindications absent.
Replaced prior broad contraindications (inadequate cardiac, renal, pulmonary, or hepatic function and significant, uncorrectable, life-limiting medical condition) with a new, more specific contraindication list addressing GFR, acute liver failure, acute renal failure, septic shock, active extrapulmonary or disseminated infection, active tuberculosis infection, HIV infection with detectable viral load, progressive cognitive impairment, and other severe uncontrolled medical conditions.
Added substance use as a contraindication (I.B.15 previously; updated list replaced with new I.B.1–6 over time).
Updated HIV-related criteria to include CD4 cell count > 200 cells/mm3, absence of active AIDS-defining opportunistic infection, and current effective antiretroviral therapy (ART).
Coverage Criteria for Tandem Hematopoietic Cell Transplant
Tandem autologous transplant (medical necessity)
Covered when ALL of the following are met:
See I.A.1-3 for detailed neuroblastoma subcriteria (stage, age, MYCN amplification, diploidy, unfavorable histology).
Policy distinguishes tandem from repeat HCT performed for relapse.
See I.B. for full contraindication parameters.
Sequential autologous then allogeneic transplant for newly diagnosed MM
Covered when ALL of the following are met:
Autologous→unrelated donor considered on a case-by-case basis.
If contraindications are present, autologous→allogeneic sequence is not medically necessary per this criterion.
Coverage conditional on meeting contraindication and HIV criteria
Coverage for tandem transplant is subject to absence of contraindications and meeting disease-specific indications referenced in current guidelines and literature.
Contraindication list condensed to I.B.1–6 in recent revisions; see policy section I.B. for full, current list.
These HIV-specific stipulations were added in the 02/24 review.
The policy language previously included a numbered criterion (IV) stating that current evidence does not support tandem transplants for indications other than those listed. That broad exclusional statement has been removed in recent revisions; the policy now operationalizes coverage through the specified medical necessity criteria and a focused contraindication list rather than an overarching blanket exclusion. The change is documented in the policy revision history indicating removal of criteria IV and minor background edits with no change to the core indications.
Earlier versions contained a general statement limiting coverage to only the indications listed, but that blanket exclusion language has been deleted. The revision history notes removal of the prior exclusionary statement and replacement of a longer contraindication list with a condensed, operational list (I.B.1–6); coverage determination is now driven by meeting the stated disease-specific indications and absence of the specified contraindications rather than by a standalone ‘‘only those indications’’ clause.
The policy distinguishes a tandem transplant from a repeat transplant performed for relapse: a tandem transplant is a prospectively planned second course of high-dose therapy and HCT occurring within six months of the first, whereas a repeat HCT performed because of disease relapse is not considered a tandem transplant and is treated as a separate scenario that does not meet the tandem-transplant criteria.
Recent document edits are described as minor background revisions that did not alter the medical necessity criteria. The revision history documents routine annual reviews and editorial updates (for example, age-related wording changes and background updates) while confirming that core coverage criteria remain in effect.
Candidate Indications and Disease-Specific Criteria
Candidate indications
Candidates for tandem autologous transplant include patients with:
NCCN recommends collecting enough hematopoietic stem cells for two transplants in eligible patients.
Background and guideline references support use in relapsed/refractory germ cell tumors.
Randomized trials reported improved EFS with tandem consolidation in high-risk neuroblastoma.
Disease-specific indications (referenced)
Indications and supporting evidence are referenced for specific malignancies.
See reference list for specific citations (e.g., Dhakal et al., Park et al., COG studies, NCCN testicular cancer guidance).
Contraindications and Factors that May Lead to Denial
The policy specifies an operational list of contraindications that, if present, may lead to denial of medical necessity for a planned tandem hematopoietic cell transplant. Key laboratory and clinical thresholds include: bilirubin > 2 mg/dL (hepatic dysfunction); INR > 1.6 (unless the member is on oral anticoagulants); and cardiac ejection fraction (EF) < 45% on MUGA or echocardiogram. Pulmonary criteria that can disqualify a candidate include FEV1 ≤ 50% predicted or DLCO ≤ 60% predicted. Performance-status thresholds that can disqualify are Karnofsky/Lansky < 70% or ECOG > 2, and uncontrolled or disseminated infection is also a contraindication.
The policy also operationalizes a broader set of clinical states that may preclude approval: acute liver failure; acute renal failure; septic shock; active extrapulmonary or disseminated infection (including active tuberculosis); progressive cognitive impairment; other severe uncontrolled medical conditions; and substance use. In addition, the revised contraindication framework references renal function limits (GFR below policy-specified thresholds) as exclusionary when documented.
For members with HIV, the policy specifies conditions under which transplantation may still be considered: the member must meet all three HIV-specific acceptance criteria — CD4 cell count > 200 cells/mm3, absence of active AIDS-defining opportunistic infection, and being currently on effective antiretroviral therapy — otherwise HIV with a detectable viral load is a contraindication.
Operationally, the presence of any of the above-listed contraindications should be documented in the medical record and will be reviewed during prior authorization and coverage verification. Providers should supply relevant laboratory results, imaging reports (e.g., MUGA/echocardiogram, pulmonary function testing), performance-status assessments, and evidence of infection evaluation to demonstrate absence of disqualifying conditions prior to approval.
This contraindication list replaced earlier, broader language and is intended to be applied consistently with clinical judgment, guideline-referenced standards, and any applicable regulatory requirements. When there is uncertainty or the member’s status is borderline, reviewers should confirm that all required documentation and evaluations have been submitted and consider case-by-case review as noted in the policy.
Contraindications that may lead to denial — major organ dysfunction or severe comorbidity
Presence of significant organ dysfunction or severe comorbidities listed in the policy contraindications may result in denial of medical necessity for a tandem transplant. Examples include: total bilirubin > 2 mg/dL; INR > 1.6 (unless on oral anticoagulants); cardiac ejection fraction < 45% on MUGA or echocardiogram; FEV1 ≤ 50% predicted or DLCO ≤ 60% predicted; and performance status below thresholds (Karnofsky/Lansky < 70% or ECOG > 2).
- Bilirubin > 2 mg/dL
- INR > 1.6 (unless on oral anticoagulants)
- Cardiac EF < 45% on MUGA or echocardiogram
- Pulmonary: FEV1 ≤ 50% predicted or DLCO ≤ 60% predicted
- Performance status: Karnofsky/Lansky < 70% or ECOG > 2
- Uncontrolled or disseminated infection
Contraindications that may lead to denial — specified clinical states
The presence of any of the policy’s specified contraindications may lead to denial of coverage for a tandem transplant; the updated contraindication list includes renal, hepatic, infectious, HIV- and cognition-related, and other severe uncontrolled conditions. Providers must confirm absence of these conditions when requesting approval.
- GFR below the policy-specified threshold (as operationalized in the contraindication list)
- Acute liver failure or acute renal failure
- Septic shock
- Active extrapulmonary or disseminated infection, including active tuberculosis
- HIV infection with detectable viral load (unless HIV-specific criteria met: CD4 > 200 cells/mm3, no active AIDS-defining opportunistic infection, and on effective ART)
- Progressive cognitive impairment or other severe uncontrolled medical condition
- Active substance use (noted in prior revisions and encompassed by the consolidated contraindications)
Coding Implications and Clinical Thresholds
| 38205 | Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic. |
| 38206 | Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous. |
| 38230 | Bone marrow harvesting for transplantation; allogeneic. |
| 38232 | Bone marrow harvesting for transplantation; autologous. |
| 38240 | Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor. |
| 38241 | Hematopoietic progenitor cell (HPC); autologous transplantation. |
| S2150 | Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre and post-transplant care in the global definition. |
| No codes listed |
Provider Actions, Documentation, and Authorization
Prior authorization required for tandem HCT
Prior authorization is required for tandem autologous transplant; requests must demonstrate the member meets all listed medical necessity criteria including eligible diagnosis, absence of contraindications, and that the second transplant is planned within six months.
- Provide diagnosis supporting one of the covered indications (e.g., newly diagnosed or responsive MM, testicular GCT, high-risk neuroblastoma).
- Document absence of contraindications in section I.B.
- Document that the second transplant is planned prospectively and to occur within six months of the first transplant.
Verify coverage and applicable NCD/LCD prior to authorization
Reviewers and providers should verify that prior authorization and any approval are consistent with the member's plan coverage and applicable Medicare/Medicaid NCDs or LCDs before proceeding with tandem transplant services.
- Confirm consistency with the member's evidence of coverage, certificate of coverage, or plan contract terms.
- For Medicare members, review applicable NCDs/LCDs before applying policy criteria.
Treatment sequencing must be prospectively planned and justified
The policy requires that tandem transplants be planned prospectively (not as repeat HCT for relapse); clinical rationale and trial evidence inform decisions about single versus tandem strategies and should be documented when seeking approval.
- Document indication-specific rationale (e.g., failure to achieve VGPR after first autologous HCT in MM or high-risk neuroblastoma trial data).
- Evidence cited (StaMINA and other trials) may be used to support the planned sequencing.
No explicit step therapy algorithm specified
No formal step therapy algorithm is provided in this policy for sequencing transplants; clinical references discuss choice between single and tandem transplant approaches but the policy does not mandate stepwise prior treatments.
- Policy emphasizes prospective planning of tandem transplant rather than a step-therapy sequence.
- Literature references discuss comparative trial outcomes informing clinical choice.
Expected clinical and procedural documentation for tandem HCT
When submitting for authorization or documentation, include clinical and procedural records such as stem cell collection/mobilization details, records of induction therapy and response, and transplant center operative and follow-up records supporting the planned second transplant within six months.
- Peripheral blood HSC collection/mobilization notes (timing and yield).
- Induction therapy regimen and documented response (e.g., VGPR status).
- Transplant center records demonstrating planned second preparative regimen and schedule within six months.
Document clinical justification and follow regulatory/plan requirements
Providers must document clinical justification and relevant evaluations consistent with standards of practice and applicable plan and regulatory requirements; state Medicaid or Medicare NCD/LCD requirements may supersede this policy.
- Retain documentation of evaluations used to establish absence of contraindications and to justify the tandem approach.
- Follow any state Medicaid or Medicare NCD/LCD requirements that may affect documentation or coverage.
Denial risk reminder — organ dysfunction/comorbidity
Presence of significant organ dysfunction or severe comorbidities listed in contraindications may lead to denial; ensure pre-authorization documentation addresses these specific contraindications and relevant labs/imaging.
- Include recent labs (bilirubin, INR), cardiac EF assessment, and pulmonary function tests when applicable.
- Document performance status and infection evaluations to demonstrate exclusion of contraindications.
Denial risk reminder — specified contraindications
Specified contraindications such as acute organ failure, septic shock, active disseminated infections, HIV with detectable viral load, progressive cognitive impairment, and other severe uncontrolled conditions can result in denial; verify and document absence of these states.
- Confirm absence of acute liver or renal failure and septic shock.
- Confirm no active extrapulmonary or disseminated infection or active tuberculosis.
- If HIV-positive, document whether viral load is detectable or if HIV-specific criteria are met (see policy).
Evaluation and Pre-Transplant Assessment
Pre-authorization evaluation requirements
Evaluation required prior to authorization should include assessment of organ function (liver, cardiac, pulmonary), performance status, infectious disease evaluation, and documentation of stem cell collection/mobilization to establish eligibility for tandem transplant.
- Liver: bilirubin and other relevant hepatic assessments.
- Cardiac: MUGA or echocardiogram with ejection fraction.
- Pulmonary: FEV1 and DLCO with percent predicted values.
- Performance status: Karnofsky/Lansky or ECOG score.
- Documentation of stem cell collection/mobilization and induction therapy response.
Definitions and Background
A tandem transplant is defined as a planned second course of high-dose therapy with hematopoietic cell transplant performed within six months of the initial transplant, prospectively scheduled to deepen and prolong response. Peripheral blood hematopoietic stem cells are collected and reserved to permit the second planned procedure.
Post-Transplant Services and Global Billing
Transplant Center and Accreditation Considerations
Center and facility expectation for tandem HCT
Tandem transplants should be performed at appropriately accredited transplant centers; the policy implies care by experienced transplant centers and references standards of practice and coding guidance.
- Ensure procedures are performed at a transplant center with relevant experience and appropriate accreditation.
- Follow center policies consistent with standards of practice and coding guidance.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.